Accelerate Diagnostics Revenue and Competitors

Tucson, AZ USA

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Accelerate Diagnostics's estimated annual revenue is currently $39.2M per year.(i)
  • Accelerate Diagnostics's estimated revenue per employee is $251,000

Employee Data

  • Accelerate Diagnostics has 156 Employees.(i)
  • Accelerate Diagnostics grew their employee count by -14% last year.

Accelerate Diagnostics's People

NameTitleEmail/Phone
1
Head Global Marketing & StrategyReveal Email/Phone
2
Head, Software EngineeringReveal Email/Phone
3
SVP, Head OperationsReveal Email/Phone
4
Head Human ResourcesReveal Email/Phone
5
Head, Scientific MarketingReveal Email/Phone
6
Head OperationsReveal Email/Phone
7
SVP, Head Research and DevelopmentReveal Email/Phone
8
Head OF Field Service Engineers EMEAReveal Email/Phone
9
Regional Business DirectorReveal Email/Phone
10
Regional Commercial Development DirectorReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$13.8M5549%N/AN/A
#2
$9.8M390%N/AN/A
#3
$0.5M40%N/AN/A
#4
$20.3M8165%N/AN/A
#5
$10.8M430%N/AN/A
#6
$28.1M112-3%$83.2MN/A
#7
$6.5M260%N/AN/A
#8
$8M190%N/AN/A
#9
$11M576%N/AN/A
#10
$12M487%N/AN/A
Add Company

What Is Accelerate Diagnostics?

Accelerate Diagnostics, Inc. (Nasdaq:AXDX), is an in vitro diagnostics company focused on developing and commercializing innovative systems for the rapid identification and antimicrobial susceptibility testing of infectious pathogens. The company's revolutionary ID/AST platform utilizes a proprietary process with both genomic and phenotypic detection technologies that significantly decreases time to result while achieving high sensitivity and specificity. In addition to the ID/AST development pipeline, the company also owns and licenses its proprietary OptiChem surface coatings technology, which has numerous applications for binding in bio-analytical systems, such as microarrays.

keywords:N/A

N/A

Total Funding

156

Number of Employees

$39.2M

Revenue (est)

-14%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Accelerate Diagnostics News

2022-04-17 - Should You Sell Accelerate Diagnostics Inc (AXDX) Stock Tuesday?

Accelerate Diagnostics Inc (AXDX) stock is down -86.90% over the last 12 months, and the average rating from Wall Street analysts is a Hold.

2022-03-30 - Accelerate Diagnostics launches Arc system for use in blood ...

In-vitro diagnostics firm Accelerate Diagnostics has launched the Accelerate Arc system for quick and accurate microbial identification of...

2022-03-30 - Accelerate Diagnostics Announces Launch Of Accelerate Arc ...

Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$17.5M15931%N/A
#2
$40.7M1629%N/A
#3
$15M1648%N/A
#4
$27.2M16515%N/A
#5
$7.5M1669%N/A